MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$33K
Net Income
-$5,479K
Net Profit Margin
-16603.03%
EPS
-$0.87
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Revenue
33
22
5
6
Cost of revenue
122
97
55
41
Amortization of acquired intangible assets
-
-
0
0
Sales and marketing
215
216
201
220
General and administrative
4,651
6,356
3,505
3,670
Research and development
2,067
1,388
1,088
790
Total operating expenses
7,055
8,057
4,849
4,721
Operating loss
-7,022
-8,035
-4,844
-4,715
Grant income
-
-
163
80
Interest income
10
19
-
-
Debt modification expense
-
-
0
0
Interest expense
2
3
-
-
Interest income
-
-
10
8
Change in fair value - equity method investment
-2,504
1,878
-
-
Interest expense
-
-
8
4
Gain on deconsolidation of subsidiary
-
-
0
-
Change in fair value - senior secured convertible notes
565
-3,360
-
-
Debt extinguishments loss - senior secured convertible notes
0
-3,422
0
0
Change in fair value - equity method investment
-
-
-4,382
-10,643
Change in fair value - warrant liability
0
-1,831
-
-
Change in fair value - senior secured convertible notes
-
-
100
200
Change in fair value - rights liability
24
30
-
-
Management fee income
3,150
3,150
3,150
3,150
Grant income
311
168
-
-
Less series b convertible preferred stock dividends earned
-
-
90
88
Other expense
0
-40
-
-
Less series c convertible preferred stock dividends earned
-
-
470
481
Other income (expense), net
424
6,971
-1,167
-7,609
Less deemed dividend on subsidiary preferred stock attributable to the noncontrolling interests
-
-
0
0
Income (loss) before provision for income tax
-6,598
-1,064
-6,011
-12,324
Provision for income taxes
0
0
0
0
Net income (loss) before noncontrolling interests
-6,598
-1,064
-6,011
-12,324
Net loss attributable to the noncontrolling interests
-1,214
-1,004
-628
-403
Net income (loss) attributable to pavmed
-5,384
-60
-5,383
-11,921
Less series b convertible preferred stock dividends earned-Series BPreferred Stock
95
94
-
-
Less series b convertible preferred stock dividends earned-Series CPreferred Stock
0
145
-
-
Less deemed dividend on series c convertible preferred stock
-
-
-385
-818
Less deemed dividend on series c convertible preferred stock-Series CPreferred Stock
0
6,689
-
-
Net income (loss) attributable to pavmed common stockholders
-5,479
-6,988
-6,328
-13,308
Basic EPS
-0.87
-4.42
-0.29
-0.74
Diluted EPS
-0.87
-4.42
-0.29
-0.74
Basic Average Shares
6,269,384
1,580,788
21,554,546
18,084,653
Diluted Average Shares
6,269,384
1,580,788
21,554,546
18,084,653
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net income (loss)
attributable to pavmed common...
-$5,479K
(58.83%↑ Y/Y)
Net income (loss)
attributable to pavmed
-$5,384K
(54.84%↑ Y/Y)
Less series b
convertible preferred stock...
$95K
Net loss
attributable to the...
-$1,214K
(-201.24%↓ Y/Y)
Net income (loss)
before noncontrolling...
-$6,598K
(46.46%↑ Y/Y)
Management fee income
$3,150K
(0.00%↑ Y/Y)
Grant income
$311K
(288.75%↑ Y/Y)
Change in fair value -
rights liability
$24K
Interest income
$10K
(25.00%↑ Y/Y)
Income (loss) before
provision for income tax
-$6,598K
(46.46%↑ Y/Y)
Other income
(expense), net
$424K
(105.57%↑ Y/Y)
Change in fair value -
equity method...
-$2,504K
(76.47%↑ Y/Y)
Change in fair value -
senior secured...
$565K
(182.50%↑ Y/Y)
Interest expense
$2K
(-50.00%↓ Y/Y)
Operating loss
-$7,022K
(-48.93%↓ Y/Y)
Revenue
$33K
(450.00%↑ Y/Y)
Total operating
expenses
$7,055K
(49.44%↑ Y/Y)
General and
administrative
$4,651K
(26.73%↑ Y/Y)
Research and development
$2,067K
(161.65%↑ Y/Y)
Sales and marketing
$215K
(-2.27%↓ Y/Y)
Cost of revenue
$122K
(197.56%↑ Y/Y)
Buy us a coffee
PAVmed Inc. (PAVM)
PAVmed Inc. (PAVM)